Tagged with R

UAE Mediclinic Middle East, the largest private healthcare group in the UAE, is betting on the continuum of care to continue thriving in a highly competitive market. CEO David Hadley explains the company’s presence in the country, with seven hospitals and 21 clinics, and provides insights into the UAE healthcare industry’s…

Czech Republic Robin Turner, general manager of Roche Czech Republic, shares how he transformed the affiliate from a “local” company to a highly engaged member of the Roche group whilst breaking down the obstacles to introducing innovative therapies and making personalized medicine a reality in the Czech Republic. Turner sees the increased…

UAE Eli Lilly’s president and general manager for the SAMETA (South Asia, Middle East, Turkey, and Africa) region, José Antonio Alas, discusses the challenges attached to overseeing 70 countries and half of the world’s population, the main opportunities for Lilly’s diabetes and oncology portfolio in the region, and the importance of…

China The Chinese healthcare market has transformed dramatically in the past few years. There have been many reforms centred around the country’s vision of becoming a healthcare technology powerhouse in the next couple of decades and ‘innovation’ has become a buzzword touted by both foreign and local players alike. But in…

Czech Republic Increasing consolidation and digitalization within the Czech pharmacy sector is forcing consumer healthcare firms to rethink their strategies.   Pharmacy Consolidation Within the Central and Eastern European (CEE) region, the pharmaceutical supply chain is relatively fragmented. However, compared to its neighbours, the Czech Republic has undergone a rapid consolidation and…

Pharma Legal Handbook The low-down on the situation regarding biosimilars & biologics in Turkey. Prepared in association with Moroğlu Arseven, a leading Turkish law firm, this is an extract from The Pharma Legal Handbook: Turkey, available to purchase here for GBP 75.   1. Are biosimilar medicines considered the same as generic medicines in…

Pharma Legal Handbook The ins and outs of localization in Turkey. Prepared in association with Moroğlu Arseven, a leading Turkish law firm, this is an extract from The Pharma Legal Handbook: Turkey, available to purchase here for GBP 75.   1. Are there any rules or regulations requiring and/or encouraging localization in your country?…

Pharma Legal Handbook Keen to learn more about orphan drugs & rare diseases in Turkey? Read on! Prepared in association with Moroğlu Arseven, a leading Turkish law firm, this is an extract from The Pharma Legal Handbook: Turkey, available to purchase here for GBP 75.   1. What is the definition of Rare Diseases…

Generics Arun Narayan is the Chairman of the Value Added Medicines Sector Group at Medicines for Europe, in addition to serving as Head of Global Portfolio Strategy and Head of European Business Operations at Mylan. Narayan introduces compelling reasons why payers in Europe should consider Value Added Medicines, including cost savings…

USA Takeda’s Jessica S. Scott examines the steps already being taken to bring greater patient engagement to drug development and the regulatory decision-making process in the USA; as well as what more needs to be done in this crucial area.   Steps Taken by FDA Under the Food and Drug Administration…

UK  A new report from the UK BioIndustry Association (BIA) asserts that the UK biotech industry is booming, despite Brexit uncertainties. Financing raised by UK biotechs in 2019 was down on the record year of 2018, but up on 2016 and 2017. Made with Visme Infographic Maker   A longer term perspective…

Hungary Hungary lags behind much of Europe in terms of healthcare spending, according to the latest OECD report on the country.     Made with Visme Presentation Maker Made with Visme Presentation Maker Made with Visme Presentation Maker